Literature DB >> 23721114

State of the art and new developments in molecular diagnostics for hemoglobinopathies in multiethnic societies.

C L Harteveld1.   

Abstract

For detecting carriers of thalassemia traits, the basic part of diagnostics consists of measurement of the hematological indices followed by mostly automatic separation and measurement of the Hb fractions, while direct Hb separation either on high pressure liquid chromatography or capillary electrophoresis is sufficient to putatively identify carriers of the common Hb variants like HbS, C, E, D, and O-Arab. A putative positive result is reported together with an advice for parents, partner, or family analysis. For couples, presumed at-risk confirmation at the DNA level is essential. In general, this part of diagnostics is done in specialized centers provided with sufficient experience and the technical tools needed to combine hematological and biochemical interpretation with identification of the mutations at the molecular level. State-of-the-art tools are usually available in centers that also provide prenatal diagnosis and should consist of gap-PCR for the common deletions, direct DNA sequencing for all kind of point-mutations and the capacity to uncover novel or rare mutations or disease mechanisms. New developments are MLPA for large and eventually unknown deletion defects and microarray technology for fine mapping and primer design for breakpoint analysis. Gap-PCR primers designed in the region flanking the deletion breakpoints can subsequently be used to facilitate carrier detection of uncommon deletions in family members or isolated populations in laboratories where no microarray technology or MLPA is available.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  MLPA; Thalassemia; hemoglobinopathy; microarray technology; molecular diagnostics; sickle cell disease

Mesh:

Substances:

Year:  2013        PMID: 23721114     DOI: 10.1111/ijlh.12108

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  7 in total

1.  Rapid and accurate diagnosis of hemoglobinopathy and β-thalassemia by ultrahigh-resolution mass spectrometry and tandem mass spectrometry from blood: review of a benchmark study.

Authors:  Laszlo Prokai
Journal:  Ann Transl Med       Date:  2019-09

2.  Prenatal diagnosis of thalassemia in 695 pedigrees from southeastern China: a 10-year follow-up study.

Authors:  Hailong Huang; Meihuan Chen; Lingji Chen; Min Zhang; Yan Wang; Na Lin; Liangpu Xu
Journal:  J Clin Lab Anal       Date:  2021-09-04       Impact factor: 2.352

3.  Detection of the sickle hemoglobin allele using a surface plasmon resonance based biosensor.

Authors:  Giulia Breveglieri; Elisabetta D'Aversa; Lucia Carmela Cosenza; Effrossyni Boutou; Angeliki Balassopoulou; Ersi Voskaridou; Roberto Gambari; Monica Borgatti
Journal:  Sens Actuators B Chem       Date:  2019-10-01       Impact factor: 7.460

4.  Molecular Detection of Alpha Thalassemia: A Review of Prevalent Techniques.

Authors:  Divashini Vijian; Wan Suriana Wan Ab Rahman; Kannan Thirumulu Ponnuraj; Zefarina Zulkafli; Noor Haslina Mohd Noor
Journal:  Medeni Med J       Date:  2021-09-30

Review 5.  The hemoglobinopathies, molecular disease mechanisms and diagnostics.

Authors:  Cornelis L Harteveld; Ahlem Achour; Sandra J G Arkesteijn; Jeanet Ter Huurne; Maaike Verschuren; Sharda Bhagwandien-Bisoen; Rianne Schaap; Linda Vijfhuizen; Hakima El Idrissi; Tamara T Koopmann
Journal:  Int J Lab Hematol       Date:  2022-09       Impact factor: 3.450

6.  Diagnosis of Sickle Cell Disease and HBB Haplotyping in the Era of Personalized Medicine: Role of Next Generation Sequencing.

Authors:  Adekunle Adekile; Nagihan Akbulut-Jeradi; Rasha Al Khaldi; Maria Jinky Fernandez; Jalaja Sukumaran
Journal:  J Pers Med       Date:  2021-05-23

7.  Breakpoint characterization of a rare alpha0 -thalassemia deletion using targeted locus amplification on genomic DNA.

Authors:  Quint P Hottentot; Emile de Meijer; Henk P J Buermans; Stefan J White; Cornelis L Harteveld
Journal:  Int J Lab Hematol       Date:  2021-07-12       Impact factor: 3.450

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.